In this study, we demonstrated that EZH2 inhibition by chidamide disrupted the activity of Smo/Gli-1 pathway and downstream signaling molecule p-AKT and increased the adriamycin sensitivity of AML cells and stem/progenitor cells. The gene discussed is AKT1; the disease is acute myeloid leukemia.